Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.74 |
| ▸ | MAPK8 | P45983 | 17/20 | 0.74 |
| ▸ | MAPK9 | P45984 | 17/20 | 0.74 |
| ▸ | MAPK10 | P53779 | 17/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 16/20 | 0.74 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5624937 | 0.89 | PIK3CA (0.83) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4345027 | 0.88 | PIK3CA (0.72) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL14506602 | 0.88 | PIK3CA (0.77) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4684872 | 0.86 | PIK3CA (0.78) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5623062 | 0.86 | PIK3CA (0.78) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL16673909 | 0.85 | PIK3CA (0.73) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5441456 | 0.85 | PIK3CA (1.00) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5454900 | 0.85 | PIK3CA (0.83) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5623757 | 0.85 | PIK3CA (0.83) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL14020860 | 0.84 | PIK3CA (0.75) | PIK3CAMAPK8MAPK9MAPK10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962854-B1 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | TERNA ZENTARIS GMBH (DE) | 2015-05-06 | — | — | EP | claimed |
| EP-1962854-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | AEterna Zentaris GmbH (DE) | 2008-09-03 | — | — | EP | claimed |
| WO-2007079999-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | ÆTERNA ZENTARIS GMBH (DE) | 2007-07-19 | — | — | WO | claimed |
| EP-1790342-A1 | Pyridopyrazine derivatives and their use as signal transduction modulators | Zentaris GmbH (DE) | 2007-05-30 | — | — | EP | claimed |
| EP-1962854-B1 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | TERNA ZENTARIS GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-8937068-B2 | Pyridopyrazine derivatives and their use | ZENTARIS GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937068-B2 | Pyridopyrazine derivatives and their use | ZENTARIS GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| EP-1962854-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | AEterna Zentaris GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007079999-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | ÆTERNA ZENTARIS GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1790342-A1 | Pyridopyrazine derivatives and their use as signal transduction modulators | Zentaris GmbH (DE) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | PIK3CA 866/4885MAPK8 116/4885MAPK9 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.